Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $1,150.00 Price Target at JPMorgan Chase & Co.

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target boosted by JPMorgan Chase & Co. from $1,050.00 to $1,150.00 in a research report released on Monday, Benzinga reports. JPMorgan Chase & Co. currently has an overweight rating on the biopharmaceutical company’s stock.

REGN has been the topic of a number of other research reports. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an outperform rating and a $1,150.00 target price on the stock. Sanford C. Bernstein started coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an outperform rating and a $1,125.00 target price for the company. TD Cowen upped their price target on Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a buy rating in a research report on Wednesday, April 24th. UBS Group lifted their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a buy rating in a report on Wednesday, April 17th. Finally, Truist Financial reissued a buy rating and set a $1,135.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. One analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of Moderate Buy and an average price target of $998.09.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock opened at $1,044.39 on Monday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. Regeneron Pharmaceuticals has a one year low of $684.80 and a one year high of $1,052.34. The stock’s 50 day moving average price is $964.87 and its 200 day moving average price is $941.08. The firm has a market capitalization of $115.08 billion, a PE ratio of 30.85, a price-to-earnings-growth ratio of 2.15 and a beta of 0.13.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. As a group, sell-side analysts expect that Regeneron Pharmaceuticals will post 37.23 EPS for the current fiscal year.

Insider Activity

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the company’s stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total value of $24,481,250.00. Following the transaction, the chief executive officer now owns 408,200 shares in the company, valued at approximately $399,729,850. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Leonard S. Schleifer sold 22,830 shares of Regeneron Pharmaceuticals stock in a transaction on Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the completion of the sale, the chief executive officer now owns 466,877 shares of the company’s stock, valued at $457,179,964.71. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the transaction, the chief executive officer now owns 408,200 shares in the company, valued at approximately $399,729,850. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 61,215 shares of company stock worth $60,414,782. 7.48% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of REGN. Vanguard Group Inc. grew its holdings in Regeneron Pharmaceuticals by 1.0% during the first quarter. Vanguard Group Inc. now owns 8,930,241 shares of the biopharmaceutical company’s stock valued at $8,595,268,000 after purchasing an additional 91,956 shares during the last quarter. Capital World Investors raised its holdings in Regeneron Pharmaceuticals by 0.5% in the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock worth $4,506,071,000 after acquiring an additional 23,146 shares during the period. Capital International Investors lifted its position in Regeneron Pharmaceuticals by 7.3% during the 1st quarter. Capital International Investors now owns 3,129,010 shares of the biopharmaceutical company’s stock worth $3,011,640,000 after acquiring an additional 213,038 shares during the last quarter. Putnam Investments LLC boosted its holdings in Regeneron Pharmaceuticals by 2.1% during the fourth quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after acquiring an additional 24,329 shares during the period. Finally, Northern Trust Corp increased its stake in shares of Regeneron Pharmaceuticals by 3.3% in the third quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock worth $878,271,000 after purchasing an additional 34,326 shares during the period. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.